Stratos Wealth Advisors LLC trimmed its stake in HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 14.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 584 shares of the company’s stock after selling 99 shares during the period. Stratos Wealth Advisors LLC’s holdings in HCA Healthcare were worth $238,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of HCA. Capital World Investors boosted its stake in HCA Healthcare by 57.5% during the 1st quarter. Capital World Investors now owns 2,792,377 shares of the company’s stock worth $931,342,000 after purchasing an additional 1,019,750 shares during the period. Lee Danner & Bass Inc. acquired a new stake in HCA Healthcare during the 2nd quarter worth $131,527,000. Darsana Capital Partners LP boosted its stake in HCA Healthcare by 53.3% during the 2nd quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock worth $369,472,000 after purchasing an additional 400,000 shares during the period. Swedbank AB acquired a new stake in shares of HCA Healthcare in the 1st quarter worth $95,882,000. Finally, TD Asset Management Inc lifted its stake in shares of HCA Healthcare by 30.4% in the 1st quarter. TD Asset Management Inc now owns 721,318 shares of the company’s stock worth $240,581,000 after acquiring an additional 168,093 shares during the period. Institutional investors and hedge funds own 62.73% of the company’s stock.
HCA Healthcare Stock Performance
Shares of NYSE HCA opened at $408.17 on Wednesday. The company has a market cap of $106.91 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. HCA Healthcare, Inc. has a 12 month low of $215.96 and a 12 month high of $417.14. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 0.94. The company has a 50-day simple moving average of $393.95 and a 200-day simple moving average of $351.69.
Analyst Ratings Changes
Several analysts have recently commented on HCA shares. Royal Bank of Canada raised their target price on shares of HCA Healthcare from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Friday, August 23rd. Barclays raised their target price on shares of HCA Healthcare from $376.00 to $396.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 24th. Morgan Stanley started coverage on shares of HCA Healthcare in a report on Tuesday, September 3rd. They issued an “equal weight” rating and a $427.00 price target for the company. Wolfe Research upgraded shares of HCA Healthcare to a “strong-buy” rating in a report on Thursday, August 29th. Finally, UBS Group increased their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $367.15.
View Our Latest Research Report on HCA
Insider Buying and Selling
In related news, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total value of $3,221,340.36. Following the sale, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other HCA Healthcare news, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $360.20, for a total transaction of $1,440,800.00. Following the transaction, the senior vice president now directly owns 40,449 shares of the company’s stock, valued at $14,569,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the transaction, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,202 shares of company stock valued at $6,407,273. Insiders own 1.60% of the company’s stock.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
See Also
- Five stocks we like better than HCA Healthcare
- Basic Materials Stocks Investing
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Use Stock Screeners to Find Stocks
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Warren Buffett Stocks to Buy Now
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.